Trądzik odwrócony – aktualny stan wiedzy i nowe możliwości terapeutyczne
Keywords:
dermatologia, HS, IL-17, leczenie biologiczne, trądzik odwróconySynopsis
Celem niniejszej pracy jest zaprezentowanie aktualnych możliwości terapeutycznych oraz przyszłych perspektyw w leczeniu trądziku odwróconego (Hidradenitis Suppurativa, HS). HS to przewlekła, zapalna choroba skóry charakteryzująca się nawracającymi, bolesnymi guzkami i ropniami, które mogą prowadzić do powstawania przetok oraz blizn. Schorzenie to najczęściej dotyczy okolic bogatych w gruczoły apokrynowe, takich jak pachy, pachwiny, okolica pośladkowa czy piersiowa i znacząco obniża jakość życia pacjentów zarówno pod względem fizycznym, jak i psychicznym. Pomimo postępów w zrozumieniu patogenezy HS, skuteczne leczenie nadal stanowi wyzwanie. W niniejszym artykule dokonano przeglądu aktualnego stanu wiedzy na temat mechanizmów chorobowych oraz dostępnych metod terapeutycznych, ze szczególnym uwzględnieniem nowych leków testowanych w badaniach klinicznych. Omówiono najnowsze strategie leczenia, w tym terapie biologiczne, inhibitory cytokin prozapalnych oraz innowacyjne podejścia farmakologiczne, które mogą zrewolucjonizować terapię HS.
References
Sabat R, Alavi A, Wolk K, et al. Hidradenitis suppurativa. The Lancet. 2025;405(10476):420-438. doi:10.1016/s0140-6736(24)02475-9
Prevalence of HS in Poland. EHSF - European Hidradenitis Suppurativa Foundation, Subspecialty Session, Berlin, 32nd EADV Congress 2023
Canoui-Poitrine F, Le Thuaut A, Revuz JE, et al. Identification of Three Hidradenitis Suppurativa Phenotypes: Latent Class Analysis of a Cross-Sectional Study. Journal of Investigative Dermatology. 2013;133(6):1506-1511. doi:10.1038/jid.2012.472
Nielsen VW, Thomsen SF, Naik HB. Hidradenitis suppurativa pathogenesis: Extrinsic factors. Journal of the American Academy of Dermatology. 2024;91(6):S17-S21. doi:10.1016/j.jaad.2024.07.1524
Goldburg SR, Strober BE, Payette MJ. Hidradenitis suppurativa. Journal of the American Academy of Dermatology. 2020;82(5):1045-1058. doi:10.1016/j.jaad.2019.08.090
Sabat R, Šimaitė D, Gudjonsson JE, et al. Neutrophilic granulocyte-derived B-cell activating factor supports B cells in skin lesions in hidradenitis suppurativa. Journal of Allergy and Clinical Immunology. 2023;151(4):1015-1026. doi:10.1016/j.jaci.2022.10.034
Del Duca E, Morelli P, Bennardo L, Di Raimondo C, Nisticò SP. Cytokine Pathways and Investigational Target Therapies in Hidradenitis Suppurativa. IJMS. 2020;21(22):8436. doi:10.3390/ijms21228436
Moran B, Sweeney CM, Hughes R, et al. Hidradenitis Suppurativa Is Characterized by Dysregulation of the Th17:Treg Cell Axis, Which Is Corrected by Anti-TNF Therapy. Journal of Investigative Dermatology. 2017;137(11):2389-2395. doi:10.1016/j.jid.2017.05.033
Witte-Händel E, Wolk K, Tsaousi A, et al. The IL-1 Pathway Is Hyperactive in Hidradenitis Suppurativa and Contributes to Skin Infiltration and Destruction. Journal of Investigative Dermatology. 2019;139(6):1294-1305. doi:10.1016/j.jid.2018.11.018
Moran B, Smith CM, Zaborowski A, et al. Targeting the NLRP3 inflammasome reduces inflammation in hidradenitis suppurativa skin. British Journal of Dermatology. 2023;189(4):447-458. doi:10.1093/bjd/ljad184
Sabat R, Gudjonsson JE, Brembilla NC, van Straalen KR, Wolk K. Biology of Interleukin-17 and Novel Therapies for Hidradenitis Suppurativa. Journal of Interferon & Cytokine Research. 2023;43(12):544-556. doi:10.1089/jir.2023.0105
Sato E, Yano N, Fujita Y, Imafuku S. Interleukin‐17A suppresses granular layer formation in a 3‐D human epidermis model through regulation of terminal differentiation genes. The Journal of Dermatology. 2020;47(4):390-396. doi:10.1111/1346-8138.15250
Shah A, Alhusayen R, Amini-Nik S. The critical role of macrophages in the pathogenesis of hidradenitis suppurativa. Inflamm Res. 2017;66(11):931-945. doi:10.1007/s00011-017-1074-y
Frew JW, Hawkes JE, Krueger JG. A systematic review and critical evaluation of inflammatory cytokine associations in hidradenitis suppurativa. F1000Res. 2018;7:1930. doi:10.12688/f1000research.17267.1
Vellaichamy G, Dimitrion P, Zhou L, et al. Insights from γ-Secretase: Functional Genetics of Hidradenitis Suppurativa. Journal of Investigative Dermatology. 2021;141(8):1888-1896. doi:10.1016/j.jid.2021.01.023
Kjærsgaard Andersen R, Clemmensen SB, Larsen LA, et al. Evidence of gene–gene interaction in hidradenitis suppurativa: a nationwide registry study of Danish twins. British Journal of Dermatology. 2022;186(1):78-85. doi:10.1111/bjd.20654
Seyed Jafari SM, Hunger RE, Schlapbach C. Hidradenitis Suppurativa: Current Understanding of Pathogenic Mechanisms and Suggestion for Treatment Algorithm. Front Med. 2020;7. doi:10.3389/fmed.2020.00068
Levra Levron C, Piacenti G, Donati G. Antibodies get under the skin. eLife. 2024;13. doi:10.7554/elife.104040
Wang B, Yang W, Wen W, et al. γ-Secretase Gene Mutations in Familial Acne Inversa. Science. 2010;330(6007):1065-1065. doi:10.1126/science.1196284
Ingram JR. The Genetics of Hidradenitis Suppurativa. Dermatologic Clinics. 2016;34(1):23-28. doi:10.1016/j.det.2015.07.002
McCarthy S, Barrett M, Kirthi S, et al. Altered Skin and Gut Microbiome in Hidradenitis Suppurativa. Journal of Investigative Dermatology. 2022;142(2):459-468.e15. doi:10.1016/j.jid.2021.05.036
Ring HC, Thorsen J, Saunte DM, et al. The Follicular Skin Microbiome in Patients With Hidradenitis Suppurativa and Healthy Controls. JAMA Dermatol. 2017;153(9):897. doi:10.1001/jamadermatol.2017.0904
Moran B, Smith CM, Zaborowski A, et al. Targeting the NLRP3 inflammasome reduces inflammation in hidradenitis suppurativa skin. British Journal of Dermatology. 2023;189(4):447-458. doi:10.1093/bjd/ljad184
Naik HB, Nassif A, Ramesh MS, et al. Are Bacteria Infectious Pathogens in Hidradenitis Suppurativa? Debate at the Symposium for Hidradenitis Suppurativa Advances Meeting, November 2017. Journal of Investigative Dermatology. 2019;139(1):13-16. doi:10.1016/j.jid.2018.09.036
Tatian A, Bordbar S, Sarkissian SD, et al. Adalimumab therapy is associated with increased faecal short chain fatty acids in hidradenitis suppurativa. Experimental Dermatology. 2022;31(12):1872-1880. doi:10.1111/exd.14665
Nosrati A, Ch’en PY, Torpey ME, et al. Efficacy and Durability of Intravenous Ertapenem Therapy for Recalcitrant Hidradenitis Suppurativa. JAMA Dermatol. 2024;160(3):312. doi:10.1001/jamadermatol.2023.6201
Frew JW. Hidradenitis suppurativa is an autoinflammatory keratinization disease: A review of the clinical, histologic, and molecular evidence. JAAD International. 2020;1(1):62-72. doi:10.1016/j.jdin.2020.05.005
van Straalen KR, Vanlaerhoven AMJD, Ardon CB, van der Zee HH. Body mass index at the onset of hidradenitis suppurativa. J Deutsche Derma Gesell. 2021;19(3):437-439. doi:10.1111/ddg.14433
Tzellos T, Zouboulis CC, Gulliver W, Cohen AD, Wolkenstein P, Jemec GBE. Cardiovascular disease risk factors in patients with hidradenitis suppurativa: a systematic review and meta-analysis of observational studies. Br J Dermatol. 2015;173(5):1142-1155. doi:10.1111/bjd.14024
Riis PT, Saunte DM, Sigsgaard V, et al. Clinical characteristics of pediatric hidradenitis suppurativa: a cross-sectional multicenter study of 140 patients. Arch Dermatol Res. 2020;312(10):715-724. doi:10.1007/s00403-020-02053-6
Miller IM, Ellervik C, Vinding GR, et al. Association of Metabolic Syndrome and Hidradenitis Suppurativa. JAMA Dermatol. 2014;150(12):1273. doi:10.1001/jamadermatol.2014.1165
Theut Riis P, Saunte DM, Benhadou F, et al. Low and high body mass index in hidradenitis suppurativa patients—different subtypes? Acad Dermatol Venereol. 2017;32(2):307-312. doi:10.1111/jdv.14599
Schneider-Burrus S, Kalus S, Fritz B, Wolk K, Gomis-Kleindienst S, Sabat R. The impact of hidradenitis suppurativa on professional life. British Journal of Dermatology. 2022;188(1):122-130. doi:10.1093/bjd/ljac027
O’Keeffe C, Kirby B. Cigarette smoking precedes the onset of hidradenitis suppurativa. Int J Dermatology. 2022;61(9). doi:10.1111/ijd.16117
Garg A, Papagermanos V, Midura M, Strunk A. Incidence of hidradenitis suppurativa among tobacco smokers: a population-based retrospective analysis in the U.S.A. Br J Dermatol. 2018;178(3):709-714. doi:10.1111/bjd.15939
Shaver RL, Jemec GBE, Freese R, Alavi A, Lowes MA, Goldfarb N. A survey of clinicians regarding preferred severity assessment tools for hidradenitis suppurativa. Int J Dermatology. 2020;60(6). doi:10.1111/ijd.15295
Revuz J. Évaluation clinique de la sévérité de l’hidradénite suppurée – maladie de Verneuil. Annales de Dermatologie et de Vénéréologie. 2015;142(12):729-735. doi:10.1016/j.annder.2015.07.012
Kimball AB, Kerdel F, Adams D, et al. Adalimumab for the Treatment of Moderate to Severe Hidradenitis Suppurativa. Ann Intern Med. 2012;157(12):846-855. doi:10.7326/0003-4819-157-12-201212180-00004
van Straalen KR, Ingram JR, Augustin M, Zouboulis CC. New treatments and new assessment instruments for Hidradenitis suppurativa. Experimental Dermatology. 2022;31(S1):33-39. doi:10.1111/exd.14609
Kimball AB, Sobell JM, Zouboulis CC, et al. HiSCR (Hidradenitis Suppurativa Clinical Response): a novel clinical endpoint to evaluate therapeutic outcomes in patients with hidradenitis suppurativa from the placebo‐controlled portion of a phase 2 adalimumab study. Acad Dermatol Venereol. 2015;30(6):989-994. doi:10.1111/jdv.13216
Ingram JR. Hidradenitis suppurativa outcome measures and treatment goals. Br J Dermatol. 2014;171(6):1293-1294. doi:10.1111/bjd.13396
Zouboulis CC, Tzellos T, Kyrgidis A, et al. Development and validation of the International Hidradenitis Suppurativa Severity Score System ( IHS 4), a novel dynamic scoring system to assess HS severity. Br J Dermatol. 2017;177(5):1401-1409. doi:10.1111/bjd.15748
Pastuszka M, Kaszuba A. Review paper Acitretin in psoriasis treatment – recommended treatment regimens. Advances in Dermatology and Allergology/Postępy Dermatologii i Alergologii. 2012;29(2):94-103
Zouboulis CC, Desai N, Emtestam L, et al. European S1 guideline for the treatment of hidradenitis suppurativa/acne inversa. Acad Dermatol Venereol. 2015;29(4):619-644. doi:10.1111/jdv.12966
Chawla S, Toale C, Morris M, Tobin AM, Kavanagh D. Surgical Management of Hidradenitis Suppurativa: A Narrative Review. J Clin Aesthet Dermatol. 2022;15(1):35-41
HAZEN PG, HAZEN BP. Hidradenitis Suppurativa. Dermatologic Surgery. 2010;36(2):208-213. doi:10.1111/j.1524-4725.2009.01427.x
Riddle A, Westerkam L, Feltner C, Sayed C. Current Surgical Management of Hidradenitis Suppurativa: A Systematic Review and Meta-Analysis. Dermatol Surg. 2021;47(3):349-354. doi:10.1097/dss.0000000000002892
DeFazio MV, Economides JM, King KS, et al. Outcomes After Combined Radical Resection and Targeted Biologic Therapy for the Management of Recalcitrant Hidradenitis Suppurativa. Annals of Plastic Surgery. 2016;77(2):217-222. doi:10.1097/sap.0000000000000584
Matusiak Ł, Walecka I, Reich A, et al. Polish guidelines for the diagnosis and treatment of hidradenitis suppurativa. pd. 2024;111(1):1-19. doi:10.5114/dr.2024.140820
Ellis CR, Azmat CE. Adalimumab. Treasure Island, FL: StatPearls Publishing; 2024
Chen SX, Greif C, Gibson RS, Porter ML, Kimball AB. Advances in biologic and small molecule therapies for hidradenitis suppurativa. Expert Opinion on Pharmacotherapy. 2022;23(8):959-978. doi:10.1080/14656566.2022.2070429
Kimball AB, Okun MM, Williams DA, et al. Two Phase 3 Trials of Adalimumab for Hidradenitis Suppurativa. N Engl J Med. 2016;375(5):422-434. doi:10.1056/nejmoa1504370
Snyder CL, Gibson RS, Porter ML, Kimball AB. Secukinumab in the Treatment of Hidradenitis Suppurativa. Immunotherapy. 2023;15(17):1449-1457. doi:10.2217/imt-2023-0103
Kimball AB, Jemec GBE, Alavi A, et al. Secukinumab in moderate-to-severe hidradenitis suppurativa (SUNSHINE and SUNRISE): week 16 and week 52 results of two identical, multicentre, randomised, placebo-controlled, double-blind phase 3 trials. The Lancet. 2023;401(10378):747-761. doi:10.1016/s0140-6736(23)00022-3
ClinicalTrials.gov
Shams RB, Sayed CJ. Bimekizumab for the treatment of hidradenitis suppurativa. Immunotherapy. 2024;16(16-17):1005-1013. doi:10.1080/1750743x.2024.2401308
Kimball AB, Jemec GBE, Sayed CJ, et al. Efficacy and safety of bimekizumab in patients with moderate-to-severe hidradenitis suppurativa (BE HEARD I and BE HEARD II): two 48-week, randomised, double-blind, placebo-controlled, multicentre phase 3 trials. The Lancet. 2024;403(10443):2504-2519. doi:10.1016/s0140-6736(24)00101-6
Golbari NM, Basehore BM, Zito PM. Brodalumab. In: StatPearls. Treasure Island (FL): StatPearls Publishing; August 8, 2023
Vagnozzi E, Bruni M, Esposito M, Fargnoli MC. Brodalumab for severe hidradenitis suppurativa: a case of clinico-radiologic improvement and literature review. Journal of Dermatological Treatment. 2023;34(1). doi:10.1080/09546634.2023.2270091
Kearney N, Hughes R, Kirby B. Treatment of hidradenitis suppurativa with brodalumab in biologic treatment failures: experiences from a specialty clinic. Clinical and Experimental Dermatology. 2023;48(7):790-792. doi:10.1093/ced/llad130
Papp KA, Weinberg MA, Morris A, Reich K. IL17A/F nanobody sonelokimab in patients with plaque psoriasis: a multicentre, randomised, placebo-controlled, phase 2b study. The Lancet. 2021;397(10284):1564-1575. doi:10.1016/s0140-6736(21)00440-2
Immunotherapeutics M. MoonLake Immunotherapeutics announces the full dataset from its 24-week MIRA clinical trial, establishing the Nanobody® sonelokimab as a highly promising and differentiated therapeutic solution for hidradenitis suppurativa. MoonLake; 2023
Kaul M, Jarvis P, Rozenberg I, et al. First‐in‐human study demonstrating the safety and clinical efficacy of novel anti‐IL‐17A monoclonal antibody CJM112 in moderate to severe plaque psoriasis. Acad Dermatol Venereol. 2021;35(5):1143-1151. doi:10.1111/jdv.17071
Kimball AB, Loesche C, Prens EP, et al. IL‐17A is a pertinent therapeutic target for moderate‐to‐severe hidradenitis suppurativa: Combined results from a pre‐clinical and phase II proof‐of‐concept study. Experimental Dermatology. 2022;31(10):1522-1532. doi:10.1111/exd.14619
Morita A, Okubo Y, Imafuku S, Terui T. Spesolimab, the first‐in‐class anti‐IL‐36R antibody: From bench to clinic. The Journal of Dermatology. 2024;51(11):1379-1391. doi:10.1111/1346-8138.17449
Alavi A, Prens EP, Kimball AB, et al. Proof-of-concept study exploring the effect of spesolimab in patients with moderate-to-severe hidradenitis suppurativa: a randomized double-blind placebo-controlled clinical trial. British Journal of Dermatology. 2024;191(4):508-518. doi:10.1093/bjd/ljae144
Alavi A, Hamzavi I, Brown K, et al. Janus kinase 1 inhibitor INCB054707 for patients with moderate‐to‐severe hidradenitis suppurativa: results from two phase II studies*. Br J Dermatol. 2022;186(5):803-813. doi:10.1111/bjd.20969
Kirby JS, Okun MM, Alavi A, et al. Efficacy and safety of the oral Janus kinase 1 inhibitor povorcitinib (INCB054707) in patients with hidradenitis suppurativa in a phase 2, randomized, double-blind, dose-ranging, placebo-controlled study. Journal of the American Academy of Dermatology. 2024;90(3):521-529. doi:10.1016/j.jaad.2023.10.034
Parmentier JM, Voss J, Graff C, et al. In vitro and in vivo characterization of the JAK1 selectivity of upadacitinib (ABT-494). BMC Rheumatol. 2018;2(1). doi:10.1186/s41927-018-0031-x
Ackerman LS, Schlosser BJ, Zhan T, et al. Improvements in moderate-to-severe hidradenitis suppurativa with upadacitinib: Results from a phase 2, randomized, placebo-controlled study. Journal of the American Academy of Dermatology. Published online February 2025. doi:10.1016/j.jaad.2024.12.046
Published
June 19, 2025
Copyright (c) 2025 Karolina Zięba, Paweł Krupa, Jakub Kmieć
License
This work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License.
